Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children.
Antibodies
Circumsporozoite protein
Plasmodium falciparum
RTS,S/AS01
Vaccines
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
02 Dec 2021
02 Dec 2021
Historique:
received:
31
07
2021
accepted:
20
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
RTS,S/AS01, the leading malaria vaccine has been recommended by the WHO for widespread immunization of children at risk. RTS,S/AS01-induced anti-CSP IgG antibodies are associated with the vaccine efficacy. Here, the long-term kinetics of RTS,S/AS01-induced antibodies was investigated. 150 participants were randomly selected from the 447 children who participated in the RTS,S/AS01 phase IIb clinical trial in 2007 from Kilifi-Kenya. Cumulatively, the retrospective follow-up period was 93 months with annual plasma samples collection. The levels of anti-CSP IgM, total IgG, IgG1, IgG2, IgG3, and IgG4 antibodies were then determined using an enzyme-linked immunosorbent assay. RTS,S/AS01 induced high levels of anti-CSP IgG antibodies which exhibited a rapid waning over 6.5 months post-vaccination, followed by a slower decay over the subsequent years. RTS,S/AS01-induced anti-CSP IgG antibodies remained elevated above the control group levels throughout the 7 years follow-up period. The anti-CSP IgG antibodies were mostly IgG1, IgG3, IgG2, and to a lesser extent IgG4. IgG2 predominated in later timepoints. RTS,S/AS01 also induced high levels of anti-CSP IgM antibodies which increased above the control group levels by month 3. The controls exhibited increasing levels of the anti-CSP IgM antibodies which caught up with the RTS,S/AS01 vaccinees levels by month 21. In contrast, there were no measurable anti-CSP IgG antibodies among the controls. RTS,S/AS01-induced anti-CSP IgG antibodies kinetics are consistent with long-lived but waning vaccine efficacy. Natural exposure induces anti-CSP IgM antibodies in children, which increases with age, but does not induce substantial levels of anti-CSP IgG antibodies.
Sections du résumé
BACKGROUND
BACKGROUND
RTS,S/AS01, the leading malaria vaccine has been recommended by the WHO for widespread immunization of children at risk. RTS,S/AS01-induced anti-CSP IgG antibodies are associated with the vaccine efficacy. Here, the long-term kinetics of RTS,S/AS01-induced antibodies was investigated.
METHODS
METHODS
150 participants were randomly selected from the 447 children who participated in the RTS,S/AS01 phase IIb clinical trial in 2007 from Kilifi-Kenya. Cumulatively, the retrospective follow-up period was 93 months with annual plasma samples collection. The levels of anti-CSP IgM, total IgG, IgG1, IgG2, IgG3, and IgG4 antibodies were then determined using an enzyme-linked immunosorbent assay.
RESULTS
RESULTS
RTS,S/AS01 induced high levels of anti-CSP IgG antibodies which exhibited a rapid waning over 6.5 months post-vaccination, followed by a slower decay over the subsequent years. RTS,S/AS01-induced anti-CSP IgG antibodies remained elevated above the control group levels throughout the 7 years follow-up period. The anti-CSP IgG antibodies were mostly IgG1, IgG3, IgG2, and to a lesser extent IgG4. IgG2 predominated in later timepoints. RTS,S/AS01 also induced high levels of anti-CSP IgM antibodies which increased above the control group levels by month 3. The controls exhibited increasing levels of the anti-CSP IgM antibodies which caught up with the RTS,S/AS01 vaccinees levels by month 21. In contrast, there were no measurable anti-CSP IgG antibodies among the controls.
CONCLUSION
CONCLUSIONS
RTS,S/AS01-induced anti-CSP IgG antibodies kinetics are consistent with long-lived but waning vaccine efficacy. Natural exposure induces anti-CSP IgM antibodies in children, which increases with age, but does not induce substantial levels of anti-CSP IgG antibodies.
Identifiants
pubmed: 34856981
doi: 10.1186/s12936-021-03961-2
pii: 10.1186/s12936-021-03961-2
pmc: PMC8641151
doi:
Substances chimiques
Antibodies, Protozoan
0
Malaria Vaccines
0
Protozoan Proteins
0
circumsporozoite protein, Protozoan
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
452Subventions
Organisme : Medical Research Council
ID : MR/P020321/1
Pays : United Kingdom
Organisme : european and developing countries clinical trials partnership
ID : TMA2016SF-1513
Informations de copyright
© 2021. The Author(s).
Références
BMC Med. 2019 Feb 25;17(1):45
pubmed: 30798787
Nat Commun. 2021 Mar 19;12(1):1742
pubmed: 33741975
N Engl J Med. 2008 Dec 11;359(24):2533-44
pubmed: 19064623
Front Immunol. 2019 Mar 15;10:439
pubmed: 30930896
Sci Adv. 2019 Sep 25;5(9):eaax4489
pubmed: 31579826
J Infect Dis. 2010 Oct 1;202(7):1076-87
pubmed: 20735271
Immunity. 2016 Aug 16;45(2):402-14
pubmed: 27473412
Open Forum Infect Dis. 2015 Aug 26;2(3):ofv118
pubmed: 26361633
Trends Microbiol. 2002 Feb;10(2):55-8
pubmed: 11827798
N Engl J Med. 2008 Dec 11;359(24):2521-32
pubmed: 19064627
Hum Vaccin. 2010 Jan;6(1):90-6
pubmed: 19806009
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33661303
Nat Biotechnol. 2015 Oct;33(10):1015-6
pubmed: 26448075
N Engl J Med. 2013 Mar 21;368(12):1111-20
pubmed: 23514288
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2425-2430
pubmed: 28193898
BMC Med. 2018 Oct 31;16(1):197
pubmed: 30376866
NPJ Vaccines. 2020 Jun 4;5:46
pubmed: 32550014
Lancet Infect Dis. 2015 Dec;15(12):1450-8
pubmed: 26342424
Immunity. 2015 Mar 17;42(3):580-90
pubmed: 25786180
BMC Med. 2014 Jul 10;12:117
pubmed: 25012228
J Infect Dis. 2009 Aug 1;200(3):337-46
pubmed: 19569965
PLoS Med. 2011 Jan 25;8(1):e1000406
pubmed: 21311579
Wellcome Open Res. 2019 Mar 5;4:42
pubmed: 31168483
Nat Immunol. 2008 Jul;9(7):725-32
pubmed: 18563083
Mol Immunol. 2015 Oct;67(2 Pt A):171-82
pubmed: 25900877
N Engl J Med. 2016 Jun 30;374(26):2519-29
pubmed: 27355532
Cell Host Microbe. 2020 Oct 7;28(4):572-585.e7
pubmed: 32697938
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272